News

Recent News

10/29/2024

Kaléo Announces Chief Development Officer

Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of Theresa Matkovits, Ph.D., as its new Chief Development Officer. Dr. Matkovits brings a wealth of experience as a transformational C-suite business leader with a strong track record of driving global drug development and commercialization efforts. With

10/28/2024

AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer’s Disease and Neuroscience Pipeline

AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Aliada’s lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for

10/25/2024

Johnson & Johnson Innovation taps new head for D.C. incubator

Johnson & Johnson Innovation announced the appointment of Rachel Rath, MBA, MPH, as the Head of JLABS @ Washington, DC, Johnson & Johnson Innovation – JLABS. Rachel assumes this role as a natural progression from her position as Director of the BARDA Alliance for Johnson & Johnson Innovation where she successfully led the management and